Thursday, December 22, 2016

Where Sarepta Therapeutics ($SRPT) is Heading in 2017

SRPT stock chart analysis

Word of caution I'd like to get out of the way first: Biotech stocks don't necessarily follow technical analysis.  However, those that show impressive technical strength can use technical analysis to predict future price(often, not always). One such stock that fits this criteria is $SRPT. 

Barring some unforeseen news such as trial deaths or severe changes in the fundamentals of the company, the technical strength shown in $SRPT will likely results in the stock receiving a significant bounce in 2017. The chart above highlights the extreme technical strength displayed a few months back, and since then the stock has pulled back. A certain degree of this pulled can be attributed to the working off the overbought condition due to the impressive move in October.

I believe in the next 6 months there will be some attempt to reach previous highs ($62.50).  As for the point to where it will bounce, it is difficult to predict. However, the price point right now may be a point where it starts to turnaround...especially as 2017 nears. 

Word of caution, I must warn again Biotech stocks are extremely risky and don't always follow technical analysis. The call I am making here is under the assumption no fundamental bad news will come during this time frame. Trade with caution (preferably don't buy risky stocks like this one).